Abstract
Efficient delivery of payload to intracellular targets has been identified as the central principle for nanomedicine development, while the extracellular targets are equally important for cancer treatment. Notably, the contribution of extracellularly distributed nanoparticles to therapeutic outcome is far from being understood. Herein, we develop a pH/light dual-responsive monochromatic ratiometric imaging nanoparticle (MRIN), which functions through sequentially lighting up the intracellular and extracellular fluorescence signals by acidic endocytic pH and near-infrared light. Enabled by MRIN nanotechnology, we accurately quantify the extracellular and intracellular distribution of nanoparticles in several tumor models, which account for 65-80% and 20-35% of total tumor exposure, respectively. Given that the majority of nanoparticles are trapped in extracellular regions, we successfully dissect the contribution of extracellularly distributed nanophotosensitizer to therapeutic efficacy, thereby maximize the treatment outcome. Our study provides key strategies to precisely quantify nanocarrier microdistribtion and engineer multifunctional nanomedicines for efficient theranostics.
Introduction
In the field of nanomedicine, the primary focus has traditionally been on achieving efficient intracellular delivery—ensuring drug payloads reach targets inside the cell. However, the complex tumor microenvironment often acts as a barrier, causing a significant portion of administered nanoparticles (NPs) to remain sequestered in the extracellular matrix (ECM) or adhered to cell membranes.
Until now, the precise quantification of these two distinct populations—intracellular versus extracellular—has been challenging due to the limitations of standard imaging techniques in living subjects. This study addresses this critical "blind spot" by introducing a monochromatic ratiometric imaging nanoparticle (MRIN) that can distinguish and quantify these distributions in vivo, revealing that the "wasted" extracellular population can be a powerful therapeutic asset.
Design and Mechanism of MRIN
The researchers engineered a dual-responsive nanoparticle system based on ultra-pH-sensitive (UPS) polymer micelles. These micelles are labeled with a fluorophore (Cy5) and a quencher (Cy7.5), utilizing Förster resonance energy transfer (FRET) to control signal output. The mechanism operates in two distinct stages:
- Intracellular Activation: At physiological pH (~7.0), the micelles remain intact, and FRET keeps the Cy5 signal in an "OFF" state. Upon endocytosis into acidic endosomes (pH ~6.0), the micelles dissociate, physically separating the fluorophore from the quencher and turning the Cy5 signal "ON."
- Extracellular Activation: To visualize the remaining extracellular particles, an external 808 nm near-infrared (NIR) laser is applied. This light selectively photobleaches the Cy7.5 quencher without affecting Cy5, thereby "lighting up" the previously quenched extracellular particles.
By capturing images before and after the NIR pulse, researchers can isolate the intracellular signal (pre-pulse) and the total signal (post-pulse). Subtracting the intracellular signal from the total provides a precise map of the extracellular distribution.
Quantifying the "Extracellular Majority"
The MRIN approach was validated across multiple tumor models, including 4T1 murine breast cancer, MCF-7 human breast cancer, and various pancreatic and colon cancer lines. The results revealed a consistent and surprising trend: the vast majority of nanoparticles—between 65% and 80%—remain in the extracellular space. In 4T1 tumors specifically, intracellular NPs accounted for only ~24% of the total exposure, while ~76% were trapped extracellularly. This highlights a massive, often ignored reservoir of therapeutic potential.
Therapeutic Implications: Activating the Wasted Reservoir
Recognizing this extracellular reservoir, the team developed a therapeutic version of the particle (MRITN) loaded with the photosensitizer Ce6. This allowed for spatially controlled photodynamic therapy (PDT):
- Intracellular PDT: Activating only the endocytosed particles achieved approximately 52% tumor growth inhibition in 4T1 models.
- Combined PDT: By also activating the extracellular population using the 808 nm laser to "prime" the particles, tumor inhibition jumped to 94.5%.
This synergy is attributed to extracellular PDT damaging the cell membrane and remodeling the ECM, which enhances the overall therapeutic impact. Furthermore, the combined treatment significantly downregulated integrin β1, reducing cell adhesion and effectively "trapping" cancer cells to prevent lung metastasis.
Conclusion and Future Directions
This study demonstrates that the extracellular distribution of nanoparticles is a significant and targetable component of tumor therapy. The monochromatic ratiometric imaging technique provides a robust tool for quantifying microdistribution without the depth-penetration issues of multi-color systems. Future research will focus on extending this dual-activation strategy to other therapeutic modalities, such as chemotherapy or immunotherapy, and exploring its utility in screening nanocarriers for better penetration in dense, desmoplastic tumors.
Summary updated